Drug Profile

Temsirolimus - Pfizer

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wyeth
Developer Johann Wolfgang Goethe Universitatsklinikum; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; National Comprehensive Cancer Network; NCIC Clinical Trials Group; Pfizer; Wyeth
Class Antineoplastics; Macrolides
Mechanism of Action MTOR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Renal cell carcinoma; Mantle-cell lymphoma
New Molecular Entity No

Marketed Mantle-cell lymphoma; Renal cell carcinoma
Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma; Thyroid cancer
Phase I/II Follicular lymphoma; Head and neck cancer
No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours
Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Australia (IV, Infusion)
28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in Canada (IV, Infusion)
28 Jul 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, Recurrent, Treatment-resistant) in USA (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com